Treatment of recurrent herpes simplex infections with L-lysine monohydrochloride

Cutis. 1984 Oct;34(4):366-73.


In a prospective, randomized, double-blind, placebo-controlled, cross-over study of forty-one patients we found that oral ingestion of 1,248 mg a day of L-Lysine monohydrochloride shows evidence of decreasing the recurrence rate of herpes simplex attacks in nonimmunocompromised hosts. A dose of 624 mg a day was not effective. L-Lysine may also be capable of decreasing the severity of symptoms associated with recurrences. Neither dosage showed any evidence of shortening the healing time compared to placebo.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Arginine / administration & dosage
  • Clinical Trials as Topic
  • Double-Blind Method
  • Electrolytes / blood
  • Herpes Simplex / blood
  • Herpes Simplex / diet therapy
  • Herpes Simplex / drug therapy*
  • Herpes Simplex / pathology
  • Humans
  • Lysine / administration & dosage
  • Lysine / therapeutic use*
  • Prospective Studies
  • Random Allocation
  • Recurrence


  • Electrolytes
  • Arginine
  • Lysine